IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11679077 B1

PDFFull Text
Date of Patent:
Jun. 20, 2023

Filed:

Jan. 19, 2021

Systems and methods for delivery of a therapeutic agent

Applicant:

The Foundry, Llc, Menlo Park, CA (US);

Inventors:

Mark E. Deem, Mountain View, CA (US);

Hanson Gifford, Woodside, CA (US);

Assignee:

The Foundry, LLC, Menlo Park, CA (US);

Attorney:

Merchant & Gould P.C.

Primary Examiner:

Albert M Navarro

Int. Cl.
CPC ...
C12M 1/00 (2006.01); A61K 9/00 (2006.01); A61K 38/16 (2006.01); A61K 38/48 (2006.01); A61K 41/00 (2020.01); A61N 1/32 (2006.01); A61N 1/08 (2006.01); A61N 1/30 (2006.01); A61N 7/00 (2006.01); A61B 18/14 (2006.01); A61B 18/18 (2006.01); A61N 5/10 (2006.01); A61M 37/00 (2006.01); A61B 18/00 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0021 (2013.01); A61B 18/1492 (2013.01); A61B 18/1815 (2013.01); A61K 9/0078 (2013.01); A61K 38/164 (2013.01); A61K 38/168 (2013.01); A61K 38/4893 (2013.01); A61K 41/00 (2013.01); A61K 41/0028 (2013.01); A61K 41/0047 (2013.01); A61M 37/00 (2013.01); A61M 37/0092 (2013.01); A61N 1/08 (2013.01); A61N 1/303 (2013.01); A61N 1/327 (2013.01); A61N 5/10 (2013.01); A61N 7/00 (2013.01); C12Y 304/24069 (2013.01); A61B 2018/0016 (2013.01); A61B 2018/00214 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/1861 (2013.01); A61M 2210/1035 (2013.01); A61N 2007/003 (2013.01); Y02A 50/30 (2018.01);
Abstract

Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.

Find Patent Forward Citations

Loading…